The estimated Net Worth of John J. Winge is at least $1.62 Millón dollars as of 1 January 2023. Mr. Winge owns over 4,868 units of SeaSpine Corp stock worth over $891,427 and over the last 9 years he sold SPNE stock worth over $0. In addition, he makes $724,073 as Vice President of Sales at SeaSpine Corp.
Sign up
Mr. Winge SPNE stock SEC Form 4 insiders trading
John has made over 6 trades of the SeaSpine Corp stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 4,868 units of SPNE stock worth $46,441 on 1 January 2023.
The largest trade he's ever made was exercising 28,430 units of SeaSpine Corp stock on 31 December 2019 worth over $271,222. On average, John trades about 2,509 units every 93 days since 2015. As of 1 January 2023 he still owns at least 93,441 units of SeaSpine Corp stock.
You can see the complete history of Mr. Winge stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Winge biography
John J. Winge serves as Vice President of Sales of the Company. Mr. Winge joined Integra in August 2008 when Integra acquired Theken Spine, LLC, a privately held medical device company focused on spine, where Mr. Winge served as executive vice president, sales and played an integral role in building Theken Spine from approximately $6 million to roughly $50 million in annual revenue. Prior to joining Theken Spine in 2004, Mr. Winge led the distribution business for REO Spine as the U.S. distributor for Eurosurgical Ltd., a distributor of surgical instrumentation and medical equipment products, from 1999 to 2004. Mr. Winge worked with various independent distributors from 1992 to 1998 as a spine hardware sales representative and manager. Mr. Winge began his medical device career as a sales representative for Sofamor Danek. Mr. Winge received a B.A. in economics from the University of Pittsburgh.
What is the salary of John Winge?
As the Vice President of Sales of SeaSpine Corp, the total compensation of John Winge at SeaSpine Corp is $724,073. There are 5 executives at SeaSpine Corp getting paid more, with Keith Valentine having the highest compensation of $1,840,570.
How old is John Winge?
John Winge is 53, he's been the Vice President of Sales of SeaSpine Corp since 2015. There are 7 older and 12 younger executives at SeaSpine Corp. The oldest executive at SeaSpine Holdings Corp is Keith Bradley, 75, who is the Independent Director.
What's John Winge's mailing address?
John's mailing address filed with the SEC is C/O SEASPINE HOLDINGS CORPORATION, 5770 ARMADA DR, CARLSBAD, CA, 92008.
Insiders trading at SeaSpine Corp
Over the last 9 years, insiders at SeaSpine Corp have traded over $2,659,931 worth of SeaSpine Corp stock and bought 297,805 units worth $3,591,897 . The most active insiders traders include Stuart Essig, Richard E Caruso y Keith Valentine. On average, SeaSpine Corp executives and independent directors trade stock every 39 days with the average trade being worth of $151,762. The most recent stock trade was executed by John J. Winge on 1 January 2023, trading 4,868 units of SPNE stock currently worth $46,441.
What does SeaSpine Corp do?
SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine's orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine's spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in both orthobiologic sciences and spinal implants product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide.
What does SeaSpine Corp's logo look like?
Complete history of Mr. Winge stock trades at SeaSpine Corp
SeaSpine Corp executives and stock owners
SeaSpine Corp executives and other stock owners filed with the SEC include:
-
Keith Valentine,
President, Chief Executive Officer, Director -
Keith C. Valentine,
Pres, CEO & Director -
John Bostjancic,
Chief Financial Officer, Senior Vice President, Treasurer -
Tyler Lipschultz,
Senior Vice President, Orthobiologics and Business Development -
Patrick Keran,
Vice President, General Counsel, Secretary -
John Winge,
Vice President of Sales -
John J. Bostjancic,
Sr. VP, CFO & Treasurer -
Patrick L. Keran,
Sr. VP, Gen. Counsel & Sec. -
Dr. Beau Standish P.Eng., Ph.D.,
Pres of Enabling Technologies -
Kimberly Commins-Tzoumakas,
Independent Director -
Renee Gaeta,
Independent Director -
Kirtley Stephenson,
Independent Non-Executive Chairman of the Board -
Stuart Essig,
Lead Independent Director -
Michael Fekete,
Independent Director -
Keith Bradley,
Independent Director -
John Henneman,
Independent Director -
Dennis Cirino,
Senior Vice President, Global Spinal Systems -
Hollis Winkler,
Sr. VP of HR -
Patrick L. Keran J.D.,
Sr. VP, Gen. Counsel & Sec. -
Dr. Frank Vizesi,
Chief Scientific Officer -
Shaeffer Bannigan,
Sr. Director of Product Devel. -
Paul Benny,
VP, Corp. Controller, Assistant Treasurer & Assistant Sec. -
Dr. Beau Standish Ph.D.,
Pres of Enabling Technologies -
Dennis L. Cirino,
Sr. VP of Global Spinal Systems -
Tyler P. Lipschultz,
Sr. VP of Orthobiologics & Bus. Devel. -
John J. Winge,
VP of Sales -
Carrie Mendivil,
Head of Investor Relations -
James M Sullivan,
Director -
Cheryl R Blanchard,
Director -
Brian D. Baker,
VP, Global Operations -
Richard E Caruso,
10% owner -
Shweta Maniar,
Director -
Life Sciences Corp Integra ...,
-
Beau Standish,
President, Enabling Tech -
Angela Steinway,
Director